RBC Affirms PTC Therapeutics (PTCT) at 'Sector Perform'; Doesn't See Translarna Appeal with Solid Chance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Sarepta Therapeutics (SRPT) Sees Intra-Day Selling Pressure
October 19, 2016 10:30 AM EDTSarepta Therapeutics (NASDAQ: SRPT) seeing notable intra-day pressure. Shares down 3.2%.
... MoreSarepta Therapeutics (SRPT) Shares Continue to Session Lows
October 19, 2016 10:30 AM EDTSarepta Therapeutics (NASDAQ: SRPT) shares are trading to session lows. The stock is down 3.6 percent with elevated volume.
... MoreCredit Suisse Starts Sarepta Therapeutic (SRPT) at Outperform
October 18, 2016 6:34 AM EDTCredit Suisse initiates coverage on Sarepta Therapeutic (NASDAQ: SRPT) with a Outperform rating and a price target of $68.00.
Analyst Alethia Young commented, "Sarepta is an RNA-based therapeutics company currently focused on drug development in Duchenne Muscular Dystrophy (DMD). Sarepta received accelerated... More
PTC Therapeutics (PTCT) Says FDA Denied First Appeal of the Refuse to File Letter
October 17, 2016 8:02 AM EDTPTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a regulatory update on Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
U.S. regulatory update
PTC Therapeutics announced today that at the end of last week, the Office of Drug Evaluation I (ODE-I) of the U.S. Food and Drug Administration (FDA) denied the company's first appeal of the refuse to file letter issued by the FDA's Division of Neurological Products (DNP) on February 22, 2016 regarding PTC's New Drug Application (NDA) for Translarna for the treatment of nonsense mutation Duchenne muscular... More
